HOME >> BIOLOGY >> NEWS
New liver cancer treatment; the current picture

In June, 2000, the Adelaidean reported on promising trials of a new technique to treat patients suffering from cancers of the liver. The researchers have now presented the preliminary results of those trials to the Annual Scientific Meeting of the Royal Australasian College of Surgeons (South Australia).

The surgical team, led by Professor Guy Maddern from Adelaide University's Department of Surgery, developed the technique of inserting electrodes into the tumours and surrounding liver tissue, and then passing small electric currents through them.

This process, termed electrolysis, destroys tumour and liver tissue in much the same way as electrolysis destroys the follicles of unwanted hair. It affects much less normal liver tissue than surgery of a more conventional kind, in which tumours are cut from the liver.

The ten patients treated so far in the ongoing trial at the Queen Elizabeth Hospital had all been evaluated as unsuitable for conventional surgical treatment due to the extent of their tumours. Nine were patients whose colonic cancers had spread to the liver, while one was treated for cancer of the liver itself.

The average follow-up time for the patients was 9 months; the shortest time being 6 months and the longest 43 months. 8 of the 10 patients showed no evidence of residual tumour at the treatment site. 5 of these 8 patients had developed new areas of tumour spread, but 3 showed no evidence of tumour recurrence.

There has been considerable worldwide interest in the trials following the initial release of the story. The Department is continuing to treat new patients using the technique, but Dr Benjamin Teague, Research Registrar in the Department of Surgery, cautions that patients must meet a number of criteria to be considered for treatment.

"They must be fit for major surgery," said Dr Teague," which means having no significant medical conditions that would make them unsuitable for a general anaesthetic
'"/>

Contact: Prof Guy Maddern
guy.maddern@adelaide.edu.au
618-8222-6000
Adelaide University
8-Nov-2001


Page: 1 2

Related biology news :

1. Gene expression in liver tumors and patient prognosis
2. The birth of reproductive health: A difficult delivery
3. Genetic discovery could dramatically reduce need for liver transplants in children
4. Macrophages, not stem cells, correct liver disease by fusion
5. Vacuum assisted deliveries are safe alternative to forceps
6. Nerac delivers journal tracking solution through TOC Journal Watch
7. Beware cancer, insomnia and liver disease UH students are taking aim
8. RNAi delivery system crosses blood-brain barrier to target brain cancer
9. Study may improve survival of transplanted livers
10. Mouse study yields clue to why liver is less prone to rejection, say Pitt researchers
11. Expression of Rb2/p130 and VEGF could serve as potential liver cancer prognosticators

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New liver cancer treatment the current picture

(Date:5/22/2013)... approach to genetic engineering drastically reduces the time ... bacteria, the workhorses of biotechnology, scientists are reporting. ... , the method paves the way for more ... environmental cleanup and other activities. , Keith Shearwin ... piece of the genetic material DNA into a ...
(Date:5/22/2013)... details on how climate change will affect interactions between ... Journal of Animal Ecology . This knowledge, they ... policymakers of how species are likely to be impacted ... growing recognition among biologists that climate change is affecting ... is going to have very important consequences for the ...
(Date:5/21/2013)... long time that some creatures evolve more quickly than ... But it may be that height plays a role, ... U. S. National Evolutionary Synthesis Center. , In ... journal Nature Communications , Lanfear and colleagues report ... a database of global patterns in plant height for ...
Breaking Biology News(10 mins):UCLA life scientists present new insights on climate change and species interactions 2UCLA life scientists present new insights on climate change and species interactions 3UCLA life scientists present new insights on climate change and species interactions 4UCLA life scientists present new insights on climate change and species interactions 5Small but speedy: Short plants live in the evolutionary fast lane 2
(Date:5/23/2013)... 2013 Venaxis, Inc. (Nasdaq:   APPY), an ... FDA clearance and commercializing its rapid, protein biomarker-based appendicitis ... an underwritten public offering of 10,000,000 shares of its ... of its common stock at an exercise price of ... of $1.25 per share and related warrant.  Venaxis has ...
(Date:5/23/2013)... May 23, 2013 PuraMed BioScience ® ... marketer of over-the-counter (OTC) medicinal and healthcare products, ... on the company based on low market capitalization ... Non-Prescription, All Natural Product to Treat Migraine Headaches ... #1 Prescription Competitor , Currently Available Nationwide ...
(Date:5/23/2013)... Calif. , May 23, 2013  Saddleback Memorial ... recently became the first hospital on the West ... technology. This new surgical option provides women with a ... Marc Winter , M.D., a ... and surgeon and medical director of minimally invasive surgery ...
(Date:5/23/2013)... , May 23, 2013 Northwest Biotherapeutics ... company developing DCVax ® personalized immune therapies for ... its exhibit at this year,s American Society Of Clinical ... to highlight its leadership role in immune therapy.  ... ASCO annual meeting is the pre-eminent conference focused on ...
Breaking Biology Technology:Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3
Cached News: